Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: INDICATIONS AND USAGE Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr… US FDA label
Kidney dosing: Calcitriol (single-agent)Show full dosing details
- eGFR ≥60
- No CKD indication at this level in the label.
- eGFR 30–59
- Predialysis secondary hyperparathyroidism (label: Ccr 15 to 55): start 0.25 mcg/day; may increase to 0.5 mcg/day. KDIGO 2017: not routinely used in G3a–G5 non-dialysis; reserve for G4–G5 with severe, progressive hyperparathyroidism.
- eGFR 15–29
- Predialysis: start 0.25 mcg/day; may increase to 0.5 mcg/day (label). KDIGO 2017: not routinely used in G3a–G5 non-dialysis; reserve for G4–G5 with severe, progressive hyperparathyroidism.
- eGFR <15 (not on dialysis)
- Label indication covers Ccr 15 to 55; below 15 not on dialysis is not addressed. Specialist input.
- Hemodialysis (intermittent)
- Start 0.25 mcg/day; increase by 0.25 mcg/day every 4 to 8 weeks; check calcium at least twice weekly during titration. Most hemodialysis patients respond to 0.5 to 1 mcg/day (label).
- Peritoneal dialysis
- Dialysis-patient dosing as above applies (label lists dialysis without modality restriction). Calcium-free dialysate PD has been used for hypercalcemia (label).
- CRRT
- Not addressed in label.
- Dialyzable? Not stated. Hypercalcemia in dialysis patients can be corrected by dialysis against a calcium-free dialysate (label).
- Monitoring Serum calcium at least twice weekly during titration; phosphorus, magnesium, alkaline phosphatase periodically; stop if hypercalcemia until normocalcemia (label). Intact PTH periodically; stop if PTH normalizes (label) and avoid oversuppression. Follow KDIGO CKD-mineral and bone disorder (CKD-MBD) targets.
From the Calcitriol monograph (renalcarematters.com, reviewed).
Use: 1. US FDA label
Use: may help reduce duration and severity of cold symptoms US FDA label
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Softgel capsule: 200 mg (equivalent to 500 mg Calcium Carbonate)/7.5 mg (equivalent to 20.588 mg Zinc Sulfate Monohydrate)/0.25 mcg
- Tablet: 225 mg/0.25 mcg/4 mg
Registered products in the Philippines
2 products registered with the Food and Drug Administration (FDA) Philippines list Calcitriol + Calcium + Zinc as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
CalpremCalcium + Calcitriol + Zinc | 225 mg/0.25 mcg/4 mg TabletPVC/Alu Blister Pack x 10's (Box of 100's) | OTC | Premier Nutraceuticals Pvt. Ltd.India | Multicare Pharmaceuticals Philippines, Inc. | DRP-10584 | Jun 27, 2027 | |
Dcal VitaCalcium + Zinc + Calcitriol | 200mg (equivalent to 500mg Calcium Carbonate) / 7.5mg (equivalent to 20.588mg Zinc Sulfate Monohydrate) / 0.25mcg Softgel CapsuleAlu/Clear Transparent PVC Blister Pack x 10's (Box of 30's) | OTC | Renown Pharmaceuticals Pvt. Ltd.India | Importer: Eon Pharmatek Inc.Trader: I-Care Formulations | DR-XY48009 | May 19, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .



